NASDAQ:ARDX

Ardelyx Stock Insider Trading

Healthcare > Biotechnology

Buy ARDX

*Your capital is at risk

$5.42

-0.1000 (-1.81%)

At Close: Jun 03, 2026

Ardelyx Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 26.47. In total, the insiders bought 5.74M and sold 637.1K ARDX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	26.47
● Buy	5.74M shares
● Sell	637.1K shares
41% Buy Activity Negligible or No Correlation
Sell Signal Low Confidence May 21, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 26.47. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 20, 2026 Sell	Common Stock S-Sale	Bishop John E See Remarks	Officer	2 792 Value: $16.4K
Feb 20, 2026 Buy	Common Stock P-Purchase	Mott David M Director	Director	333 333 Value: $1.95M
Feb 20, 2026 Sell	Common Stock S-Sale	Reilly Joseph James See Remarks	Officer	2 Value: $11
Feb 20, 2026 Sell	Common Stock S-Sale	Williams Laura A See Remarks	Officer	7 192 Value: $42.2K
Feb 20, 2026 Sell	Common Stock S-Sale	Williams Laura A See Remarks	Officer	984 Value: $6K
Feb 20, 2026 Sell	Common Stock S-Sale	Hohenleitner Susan Chief Financial Officer	C-Suite Officer	1 786 Value: $10.5K
Feb 20, 2026 Sell	Common Stock S-Sale	Hohenleitner Susan Chief Financial Officer	C-Suite Officer	247 Value: $1K
Feb 20, 2026 Sell	Common Stock S-Sale	Brady James Parker Chief Human Resources Officer	Officer	2 234 Value: $13.1K
Feb 20, 2026 Sell	Common Stock S-Sale	Kelliher Mike See Remarks	Officer	8 434 Value: $49.5K
Feb 20, 2026 Sell	Common Stock S-Sale	Kelliher Mike See Remarks	Officer	2 Value: $11
Jan 23, 2026 Buy	Common Stock A-Award	Reilly Joseph James See Remarks	Officer	46 200 Value: $359.0K
Jan 23, 2026 Buy	Stock Option (Right to Buy) A-Award	Reilly Joseph James See Remarks	Officer	69 360 Value: $538.9K
Jan 23, 2026 Buy	Stock Option (Right to Buy) A-Award	Williams Laura A Chief Patient Officer	Officer	124 040 Value: $963.8K
Jan 23, 2026 Buy	Common Stock A-Award	Williams Laura A Chief Patient Officer	Officer	82 695 Value: $642.5K
Jan 23, 2026 Buy	Common Stock A-Award	Brady James Parker Chief Human Resources Officer	Officer	99 455 Value: $772.8K
Jan 23, 2026 Buy	Stock Option (Right to Buy) A-Award	Hohenleitner Susan Chief Financial Officer	C-Suite Officer	128 505 Value: $998.5K
Jan 23, 2026 Buy	Common Stock A-Award	Hohenleitner Susan Chief Financial Officer	C-Suite Officer	85 670 Value: $665.7K
Jan 23, 2026 Buy	Stock Option (Right to Buy) A-Award	Kelliher Mike See Remarks	Officer	154 625 Value: $1.20M
Jan 23, 2026 Buy	Common Stock A-Award	Kelliher Mike See Remarks	Officer	103 080 Value: $800.9K
Jan 23, 2026 Buy	Common Stock A-Award	Foster Eric Duane Chief Commercial Officer	Officer	137 945 Value: $1.07M
Jan 23, 2026 Buy	Stock Option (Right to Buy) A-Award	Foster Eric Duane Chief Commercial Officer	Officer	206 915 Value: $1.61M
Jan 23, 2026 Buy	Common Stock A-Award	Raab Michael President & CEO	CEO / President	446 220 Value: $3.47M
Jan 23, 2026 Buy	Stock Option (Right to Buy) A-Award	Raab Michael President & CEO	CEO / President	669 330 Value: $5.20M
Jan 23, 2026 Buy	Stock Option (Right to Buy) A-Award	Brady James Parker Chief Human Resources Officer	Officer	149 185 Value: $1.16M
Jan 23, 2026 Buy	Common Stock A-Award	Bishop John E See Remarks	Officer	124 330 Value: $966.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ARDELYX

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult pat...

Read Full Profile Here